Introduction: energy sealing devices achieve hemostasis of the vessels through the heat generated and coagulation of the vascular wall's proteins. However, mid-term efficacy for venous graft sealing in arterial bypass surgery, remains unknown Objectives: to create an animal model which allows the comparison of mid-term efficacy and safety at the sealing zone after the healing process. To compare and assess which in vivo arterial models show lower morbidity and higher survival after 4 weeks postoperative. Material and methods: an in vivo experimental study of 16 New Zealand rabbits. In each rabbit a human saphenous vein (SV) with at least one venous collateral was implanted. Two arterial models were developed: infrarrenal aorta bypass with SV (n = 5) and aortoplasty with SV patch (n = 11). In both models the collateral was randomized ad sealed with one energy sealing devices: Electrothermal Bipolar Vessel Sealing (EBVS) or Harmonic scalpel (HS). Every animal was treated with antithrombotic prophylaxis and immunosuppressive medication. Intraoperative mortality, paraplegia, infection, bleeding, and survival was analyzed. Results: two animals (50 %) survive at the 7th postoperative day in the bypass model, but anyone survived the four weeks postoperative in this model. In the aortoplasty group, seven-day survival was 55,56 % (5/9) and 4-weeks survival was 44,44 % (4/9) (p = 0.05). Paraplegia rate was 100 % for the bypass model and much lower for the patch group (25 %) (p = 0,03). Mean ischemic time was lower for the aortoplasty model (37,11 ± 8,1 min) compared to bypass group (42 ± 10,61 min) (p = 0.414). No animal presented intrabdominal hemorrhage or adverse drug reaction for immunosuppressive medication. Conclusion: aortoplasty with SV patch model has shown a lower paraplegia rate and a lower mortality at 7 days in the animal model performed. Both bypass model and patch model have shown efficacy at the sealing zone but only in the aortoplasty model four animals survived after 4 weeks.